Mar 19 |
ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
|
Mar 16 |
US$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These Results
|
Mar 15 |
ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Earnings Call Transcript
|
Mar 14 |
Q4 2023 ADC Therapeutics SA Earnings Call
|
Mar 13 |
ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript
|
Mar 13 |
ADC Therapeutics SA 2023 Q4 - Results - Earnings Call Presentation
|
Mar 13 |
ADC Therapeutics SA (ADCT) Reports Mixed 2023 Financial Results Amid Strategic Reset
|
Mar 13 |
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
|
Mar 13 |
ADC Therapeutics Non-GAAP EPS of -$0.97, revenue of $16.79M beats by $1.53M
|
Mar 13 |
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
|